ASPEAspen Neuroscience, Inc.vs its industry peers
A metric-by-metric comparison of Aspen Neuroscience, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASPEEsta | — | — | — | — | — | — | — | — | — | — | — | — |
| AKTX | $1.41T#1 | — | 75596.7x#3 | 3821170.5x#3 | -39.5%#3 | 12.6%#6 | -4695.9%#4 | -93.0%#4 | -155.6%#1 | — | -68.0%#3 | — |
| ALMS | $744M#3 | — | 1.6x#1 | 31.0x#2 | — | 17.3%#5 | -1886.9%#3 | -53.8%#3 | — | — | — | — |
| APLM | $43M#4 | — | — | — | — | 68.8%#2 | — | — | — | — | — | — |
| APLMW | $23059#6 | — | — | — | — | 68.8%#2 | — | — | — | — | — | — |
| AUPH | $2.2B#2 | 7.2x#1 | 3.3x#2 | 7.7x#1 | 20.4%#1 | 4851.7%#1 | 37.1%#1 | 43.7%#1 | — | — | 13.0%#2 | — |
| AZN | — | — | — | — | 8.6%#2 | 45.3%#4 | 23.4%#2 | 21.0%#2 | — | — | 131.4%#1 | — |
| BCTXL | $7M#5 | — | — | — | — | -32.7%#7 | — | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-06.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice